Minghui Pharmaceutical to present phase I/II study of MHB088C (B7-H3 ADC) for recurrent or metastatic solid tumors at 2024 ASCO meeting

CAR-T Digest - August 2020

Weekly Digest - May 2024

14 May 2024: Minghui Pharmaceutical to present phase I/II study of MHB088C (B7-H3 ADC) for recurrent or metastatic solid tumors at 2024 ASCO meeting

Minghui Pharmaceutical will present Phase III clinical study results of MHB088C, a B7-H3-targeting antibody-drug conjugate (ADC), for recurrent or metastatic solid tumors
MHB088C, developed with Minghui’s SuperTopoiTM ADC platform, is 5 to 10 times more potent than the competitor’s Dxd
Preclinical studies indicated an excellent safety profile with no unique toxicities, particularly no pulmonary toxicities
The Phase III study has enrolled over 150 patients with different tumor types, demonstrating promising efficacy and a favorable safety profile
Registrational trials for selected tumor types are expected to begin by the end of the year